Second Generation DICART Prototype Validation (DICART II)

Capillary refill time (CRT) is a clinical sign for diagnosis of acute circulatory failure and response to treatment but is also associated with prognosis in patient with shock. CRT is clinically evaluated by physician with a high risk of inter and intra evaluator variations, depending, for example, on measurement site, pressure applicated or visual evaluation. The investigator hypothesizes that CRT measurement with second generation DICART prototype will be well correlated with clinical measurement.

Capillary refill time is measured by two independent operators, each one blinded from the other, with second generation DICART prototype. Each operator performs two series of three consecutive measurement on the finger. Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax

Capillary refill time is clinically measured by two independent operators, each one blinded from the other. Each operator performs, two series of three consecutive measurement on the second finger. Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax, inverted relative to DICART measurements.

Intraclass correlation coefficient between clinical and automatic DICART capillary refill time measurement.

Intraclass correlation coefficient between clinical and automatic DICART capillary refill time measurement.

ROC curve for DICART performance to detect a tissular hypoperfusion, defined as a clinical CRT superior to 3s

Safety consideration about DICART use: qualitative skin examination pain evaluation by numerical rating scale (0 means none and 3 severe)

Safety consideration about DICART use: pain evaluation by numerical rating scale 0 corresponds to "no pain" and 10 to "worst pain imaginable".

Inclusion Criteria: ->18 years old Acute circulatory failure Written informed consent given by patient or its relatives Exclusion Criteria: Pregnant women, breastfeeding women, childbearing age women without oral contraception Cutaneous lesion at measurement site Patient under legal protection Patient already included in another interventional clinical trial